Large-scale pharmacological profiling of 3D tumor models of cancer cells

The discovery of chemotherapeutic agents for the treatment of cancer commonly uses cell proliferation assays in which cells grow as two-dimensional (2D) monolayers. Compounds identified using 2D monolayer assays often fail to advance during clinical development, most likely because these assays do not reproduce the cellular complexity of tumors and their microenvironment in vivo. The use of three-dimensional (3D) cellular systems have been explored as enabling more predictive in vitro tumor models for drug discovery. To date, small-scale screens have demonstrated that pharmacological responses tend to differ between 2D and 3D cancer cell growth models. However, the limited scope of screens using 3D models has not provided a clear delineation of the cellular pathways and processes that differentially regulate cell survival and death in the different in vitro tumor models. Here we sought to further understand the differences in pharmacological responses between cancer tumor cells grown in different conditions by profiling a large collection of 1912 chemotherapeutic agents. We compared pharmacological responses obtained from cells cultured in traditional 2D monolayer conditions with those responses obtained from cells forming spheres versus cells already in 3D spheres. The target annotation of the compound library screened enabled the identification of those key cellular pathways and processes that when modulated by drugs induced cell death in all growth conditions or selectively in the different cell growth models. In addition, we also show that many of the compounds targeting these key cellular functions can be combined to produce synergistic cytotoxic effects, which in many cases differ in the magnitude of their synergism depending on the cellular model and cell type. The results from this work provide a high-throughput screening framework to profile the responses of drugs both as single agents and in pairwise combinations in 3D sphere models of cancer cells.

[1]  H. B. Mann,et al.  On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .

[2]  Ruili Huang,et al.  A Grid Algorithm for High Throughput Fitting of Dose-Response Curve Data , 2010, Current chemical genomics.

[3]  R. Herrmann,et al.  Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids , 2008, Journal of biomolecular screening.

[4]  Jing Zhou,et al.  Establishment of Clonal Colony-Forming Assay for Propagation of Pancreatic Cancer Cells With Stem Cell Properties , 2007, Pancreas.

[5]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[6]  G. Botchkina,et al.  Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. , 2008, Cancer genomics & proteomics.

[7]  Massimo Cristofanilli,et al.  Imaging and Analysis of 3D Tumor Spheroids Enriched for a Cancer Stem Cell Phenotype , 2010, Journal of biomolecular screening.

[8]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[9]  Lesley A. Mathews,et al.  DNA repair: the culprit for tumor-initiating cell survival? , 2011, Cancer and Metastasis Reviews.

[10]  Young Seok Kim,et al.  Long‐term recovery of irradiated prostate cancer increases cancer stem cells , 2012, The Prostate.

[11]  R. Seethala,et al.  Handbook of drug screening , 2001 .

[12]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[13]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[14]  I. Kang,et al.  Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. , 2008, Carcinogenesis.

[15]  C. D. Salcido,et al.  Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics , 2008, Breast Cancer Research.

[16]  M. Hummel,et al.  Evidence for Epithelial-Mesenchymal Transition in Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma , 2011, PloS one.

[17]  R. Fisher On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2018, Journal of the Royal Statistical Society Series A (Statistics in Society).

[18]  C. Giordano,et al.  Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells , 2010, Bioscience reports.

[19]  Sam Michael,et al.  High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations , 2015, Scientific Reports.

[20]  Matthias Gutekunst,et al.  Three‐dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo , 2014, Biotechnology journal.

[21]  Lesley A. Mathews,et al.  Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells , 2011, Pancreas.

[22]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[23]  Kenneth M. Yamada,et al.  Modeling Tissue Morphogenesis and Cancer in 3D , 2007, Cell.

[24]  G. Ceresoli,et al.  Use of dose-volume histograms and biophysical models to compare 2D and 3D irradiation techniques for non-small cell lung cancer. , 1999, The British journal of radiology.

[25]  J. Kelm,et al.  Development of an Innovative 3D Cell Culture System to Study Tumour - Stroma Interactions in Non-Small Cell Lung Cancer Cells , 2013, PloS one.

[26]  A. Schönthal,et al.  Induction of p21 Mediated by Reactive Oxygen Species Formed during the Metabolism of Aziridinylbenzoquinones by HCT116 Cells* , 1996, The Journal of Biological Chemistry.

[27]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Mary Kay Harper,et al.  3D Models of Epithelial-Mesenchymal Transition in Breast Cancer Metastasis , 2011, Journal of biomolecular screening.

[29]  R. Qin,et al.  Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells , 2011, Digestive Diseases and Sciences.

[30]  Lesley A. Mathews,et al.  Epigenetic Regulation of SOX9 by the NF‐κB Signaling Pathway in Pancreatic Cancer Stem Cells , 2013, Stem cells.

[31]  M. Bennett,et al.  Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats , 2011, Drug Metabolism and Disposition.

[32]  Lesley A. Mathews,et al.  Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells , 2010, Molecular Cancer.

[33]  Paul Shinn,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[34]  Lesley A. Mathews,et al.  DNA Repair of Cancer Stem Cells , 2013, Springer Netherlands.

[35]  G. Fròsina DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy , 2009, Molecular Cancer Research.

[36]  M. Fournier,et al.  Transcriptome profiling in clinical breast cancer: From 3D culture models to prognostic signatures , 2006, Journal of cellular physiology.

[37]  K. Papadopoulos,et al.  Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib , 2013, Drug Metabolism and Disposition.

[38]  Marilena Loizidou,et al.  3D tumour models: novel in vitro approaches to cancer studies , 2011, Journal of Cell Communication and Signaling.

[39]  M. Gottesman,et al.  Beyond 3D culture models of cancer , 2015, Science Translational Medicine.

[40]  Lesley A. Mathews,et al.  A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells , 2012, Journal of biomolecular screening.

[41]  V. Virador,et al.  In vitro three‐dimensional (3D) models in cancer research: An update , 2013, Molecular carcinogenesis.

[42]  Lesley A. Mathews,et al.  Targeting Cancer Stem Cell Efficient DNA Repair Pathways: Screening for New Therapeutics , 2013 .

[43]  R. Fisher On the Interpretation of χ2 from Contingency Tables, and the Calculation of P , 2010 .